Del(17p) / TP53
Other names: del(17p), TP53 mutation, high risk cytogenetics
17p deletion and TP53 mutation are high-risk cytogenetic factors in multiple myeloma.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Plain explanation
This examination looks for changes in chromosomes and genes related to how cells repair damage. Certain changes make the disease more difficult to control with standard therapy.
Clinical meaning
The presence of del(17p) or TP53 mutations may change how medical teams discuss therapeutic strategies and the feasibility of clinical trials in high-risk multiple myeloma.
Testing methods
- Multiple myeloma FISH panel
A cytogenetic test to detect chromosome changes linked to risk in multiple myeloma.
- Next-generation sequencing (NGS)
A test that reads many genes from one tumour sample to find actionable changes.
- Bone marrow biopsy and aspiration
Collection of bone marrow to assess plasma cells and blood production.
A negative result does not always mean the marker is absent
Test sensitivity differs by sample type and method. Results need to be read together with the pathology report and clinical condition.
What needs verification
- FISH results that state the percentage of abnormal cells.
- Have an examination done on the new bone marrow.
- History of previous therapy and response noted.
- Eligibility criteria for clinical trials for high-risk diseases.
Related drugs
- Bortezomib
Proteasome inhibitor
- Carfilzomib
Second generation proteasome inhibitor
- Daratumumab
Anti-CD38 monoclonal antibody
- Venetoclax
BCL-2 inhibitor
- Selinexor
Exportin-1 (XPO1) inhibitors
A link here means the marker is often part of considering a drug category, not a recommendation to use it.
Guides discussing this marker
Written to help prepare questions and documents, not to replace a doctor's assessment.
Clinical trials
Studies mentioning this marker
Filtered from public study descriptions. Access status and site readiness remain unverified.
NO DATA
No studies in the latest registry data mention this marker in their description.
Check options based on your result
Share the Del(17p) / TP53 result you have so we can explain which categories to discuss with a doctor.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- Leukemia
Subtype
Reason: Related through a biomarker
- Multiple Myeloma
Cancer type
Reason: Related through a biomarker
- CAR-T (chimeric antigen receptor T-cell therapy)
Treatment category
Reason: Related through a biomarker
- Targeted therapy
Treatment category
Reason: Related through a biomarker
- Bortezomib
Drug
Reason: Targets this marker
- Carfilzomib
Drug
Reason: Targets this marker
To check
- Bone marrow biopsy and aspiration
Diagnostic test
Reason: Diperiksa melalui
- Multiple myeloma FISH panel
Diagnostic test
Reason: Diperiksa melalui
- Next-generation sequencing (NGS)
Diagnostic test
Reason: Diperiksa melalui
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.